Stocks · News reference
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced that its management team will participate in two major investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. Both events will feature fireside chats and one-on-one meetings with investors. Live webcasts and 90-day archived recordings will be available on the company's investor relations website.
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.